Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
Condition: Carcinoma, Non-Small-Cell Lung
MeSH terms: Carcinoma, Non-Small-Cell Lung
Intervention: Afatinib
Intervention description: Patient will receive afatinib once daily
Intervention MeSH terms: Afatinib
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 542.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      Primary objective of the trial is to evaluate the safety of afatinib in patients with locally
      advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR (Epidermal growth
      factor receptor) mutation(s) and have never been treated with an EGFR-TKI (tyrosine kinase
      inhibitor). Secondary objective is to assess the time to symptomatic progression (as judged
      by investigator).
    

Eligibility criteria:

        Inclusion criteria:

          -  locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC)

          -  presence of Epidermal Growth Factor Receptor (EGFR) mutations in tumor biopsy

          -  male or female patients age 18 years or older (For India only, male or female patients
             age >=18 years and <=75 years)

          -  adequate organ function, defined as all of the following:

               1. Absolute Neutrophil Count (ANC) > 1500/mm3. (ANC >1000/mm3 may be considered in
                  special circumstances such as benign cyclical neutropenia as judged by the
                  investigator and in discussion with the sponsor).

               2. Platelet count >75,000/mm3

               3. Serum creatinine < 1.5 times of the upper limit of normal

               4. Total Bilirubin < 1.5 times upper limit of (institutional) normal (Patients with
                  Gilbert's syndrome total bilirubin must be <4 times institutional upper limit of
                  normal).

               5. Aspartate Amino Transferase (AST) and Alanine Amino Transferase (ALT) < three
                  times the upper limit of (institutional) normal (ULN) (if related to liver
                  metastases < five times ULN). 5) Eastern Cooperative Oncology Group (ECOG) score
                  between 0 - 2 6) written informed consent by patient or guardian prior to
                  admission into the trial that is consistent with International Conference on
                  Harmonisation (ICH)- Good Clinical Practice (GCP) guidelines and local law.

        Exclusion criteria:

          -  prior treatment with an EGFR tyrosine kinase inhibitor (TKI)

          -  use of anti-cancer treatment within 2 weeks prior to start of trial treatment
             (continued use of anti-androgens and / or gonadorelin analogues for treatment of
             prostate cancer permitted)

          -  radiotherapy within 4 weeks prior to drug administration except as follows:

               1. palliative radiation to organs other than chest may be allowed up to 2 weeks
                  prior to drug administration, and

               2. single dose palliative treatment for symptomatic metastasis outside above
                  allowance to be discussed with sponsor prior to enrolling.

          -  major surgery within 4 weeks from day 1 of first dose of afatinib. At least 7 days
             should have elapsed since minor surgical procedure including placement of an access
             device or fine needle aspiration and at least 14 days for diagnostic or palliative
             video-assisted thoracoscopic surgery (VATS).

          -  known hypersensitivity to afatinib or any of its excipients

          -  history or presence of clinically relevant cardiovascular abnormalities such as
             uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA)
             classification of >3, unstable angina or poorly controlled arrhythmia as determined by
             the investigator. Myocardial infarction within 6 months prior to starting trial
             treatment.

          -  Women of Child-Bearing Potential (WOCBP) and men who are able to father a child,
             unwilling to be abstinent or use medically acceptable method of contraception during
             the trial entry and for at least 4 weeks after treatment has ended. Adequate methods
             of contraception and Women of Child-Bearing Potential. Perimenopausal women must be
             amenorrhoeic for at least 24 months to be considered for non-childbearing potential.

          -  childbearing potential (see Section 4.2.3) who:

               1. are nursing or

               2. are pregnant or

               3. are not using an acceptable method of birth control, or do not plan to continue
                  using this method throughout the trial and/or do not agree to submit to pregnancy
                  testing required by this protocol

          -  history of or co-existing condition that, in the opinion of the investigator, would
             compromise the patient's ability to comply with the trial or interfere with the
             evaluation of safety for the trial drug

          -  previous or concomitant malignancies at other sites, except effectively treated
             nonmelanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or
             effectively treated malignancy that has been in remission for more than 3 years and is
             considered to be cured.

          -  requiring treatment with any of the prohibited concomitant medications listed, that
             cannot be stopped for the duration of trial participation

          -  known pre-existing interstitial lung disease

          -  presence of poorly controlled gastrointestinal disorders that could affect the
             absorption of the trial drug (e.g. Crohn's disease, ulcerative colitis, malabsorption,
             or CTC grade =2 diarrhoea of any aetiology) based on investigator assessment.

          -  Known active hepatitis B infection (defined as presence of Hepatitis B (HepB) sAg
             and/or HepB DNA), active Hepatitis C (HEP C) infection (defined as presence of Hep C
             RNA) and/or known Human Immunodeficiency Virus (HIV) carrier.

          -  meningeal carcinomatosis

          -  symptomatic brain metastases (patients with brain metastases, who were previously
             treated, are eligible provided they have asymptomatic brain metastasis for at least 4
             weeks on stable doses of medication)